BCM
CRMD icon

BlueCrest Capital Management’s CorMedix CRMD Stock Holding History

BlueCrest Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-45,231
Closed -$427K – 547
2019
Q1 		$427K Buy
+45,231
New +$408K 0.02% 543

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
SC
Spinnaker Capital Boston, Massachusetts $1.08M AUM 45.28% 1-Year Est. Return

BlueCrest Capital Management's CRMD Position: Q2 2019 in Review

BlueCrest Capital Management sold out of CorMedix (CRMD) in Q2 2019, closing a stake of 45,231 shares — an estimated $427K sold.

BlueCrest Capital Management first reported a position in CRMD in Q1 2019 and held it in 1 quarter. The position peaked at $427K in Q1 2019. 47 funds tracked by Wall St. Rank hold CRMD as of Q2 2019.

  • BlueCrest Capital Management reported no remaining CorMedix position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 45,231 CorMedix shares in Q2 2019, an estimated $427K.
  • BlueCrest Capital Management first reported a position in CorMedix in Q1 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's CorMedix position peaked at $427K in Q1 2019.
  • 47 funds tracked by Wall St. Rank held CorMedix as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.